BAY 2476568

BAY 2476568 is an investigational **small-molecule epidermal growth factor receptor inhibitor** being developed by Bayer in collaboration with the Broad Institute for **non-small-cell lung cancer with EGFR exon 20 insertion mutations**. It is described as a **potent, selective, reversible EGFR tyrosine kinase inhibitor** with preferential activity against multiple EGFR exon 20 insertion variants, while also retaining activity against classical activating EGFR mutations and the **C797S** resistance setting in preclinical studies. The program has been presented in preclinical cancer models, including xenografts, and is intended to address a genomically defined NSCLC population that is often resistant to earlier-generation EGFR inhibitors.